203 related articles for article (PubMed ID: 38555285)
1. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Giudice E; Huang TT; Nair JR; Zurcher G; McCoy A; Nousome D; Radke MR; Swisher EM; Lipkowitz S; Ibanez K; Donohue D; Malys T; Lee MJ; Redd B; Levy E; Rastogi S; Sato N; Trepel JB; Lee JM
Nat Commun; 2024 Mar; 15(1):2805. PubMed ID: 38555285
[TBL] [Abstract][Full Text] [Related]
2. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
3. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Cho HY; Kim YB; Park WH; No JH
Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
[TBL] [Abstract][Full Text] [Related]
5. Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer.
Nair J; Huang TT; Murai J; Haynes B; Steeg PS; Pommier Y; Lee JM
Oncogene; 2020 Aug; 39(33):5520-5535. PubMed ID: 32647134
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
Konstantinopoulos PA; Lee JM; Gao B; Miller R; Lee JY; Colombo N; Vergote I; Credille KM; Young SR; McNeely S; Wang XA; Lin AB; Shapira-Frommer R
Gynecol Oncol; 2022 Nov; 167(2):213-225. PubMed ID: 36192237
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of prexasertib monotherapy in recurrent
Lampert EJ; Cimino-Mathews A; Lee JS; Nair J; Lee MJ; Yuno A; An D; Trepel JB; Ruppin E; Lee JM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32709712
[TBL] [Abstract][Full Text] [Related]
8.
Gupta N; Huang TT; Nair JR; An D; Zurcher G; Lampert EJ; McCoy A; Cimino-Mathews A; Swisher EM; Radke MR; Lockwood CM; Reichel JB; Chiang CY; Wilson KM; Cheng KC; Nousome D; Lee JM
Sci Transl Med; 2023 Jun; 15(701):eadd7872. PubMed ID: 37343085
[TBL] [Abstract][Full Text] [Related]
9. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Shah PD; Wethington SL; Pagan C; Latif N; Tanyi J; Martin LP; Morgan M; Burger RA; Haggerty A; Zarrin H; Rodriguez D; Domchek S; Drapkin R; Shih IM; Smith SA; Dean E; Gaillard S; Armstrong D; Torigian DA; Hwang WT; Giuntoli R; Simpkins F
Gynecol Oncol; 2021 Nov; 163(2):246-253. PubMed ID: 34620496
[TBL] [Abstract][Full Text] [Related]
10. Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer.
Evangelisti G; Barra F; Moioli M; Sala P; Stigliani S; Gustavino C; Costantini S; Ferrero S
Expert Opin Investig Drugs; 2020 Aug; 29(8):779-792. PubMed ID: 32539469
[TBL] [Abstract][Full Text] [Related]
11. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
[TBL] [Abstract][Full Text] [Related]
13. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
14. A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN).
Lee YJ; Seol A; Lee M; Kim JW; Kim HS; Kim K; Suh DH; Kim S; Kim SW; Lee JY
In Vivo; 2022; 36(4):1949-1958. PubMed ID: 35738633
[TBL] [Abstract][Full Text] [Related]
15. Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
Lee JM; Moore RG; Ghamande S; Park MS; Diaz JP; Chapman J; Kendrick J; Slomovitz BM; Tewari KS; Lowe ES; Milenkova T; Kumar S; Dymond M; Brown J; Liu JF
Clin Cancer Res; 2022 Oct; 28(19):4186-4193. PubMed ID: 35917514
[TBL] [Abstract][Full Text] [Related]
16. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
[No Abstract] [Full Text] [Related]
17. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel B; Buss MK; Nattam S; Hurteau J; Luo W; Quy P; Whalen C; Obermayer L; Lee H; Winer EP; Kohn EC; Ivy SP; Matulonis UA
Lancet Oncol; 2014 Oct; 15(11):1207-14. PubMed ID: 25218906
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Do KT; Kochupurakkal B; Kelland S; de Jonge A; Hedglin J; Powers A; Quinn N; Gannon C; Vuong L; Parmar K; Lazaro JB; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2021 Sep; 27(17):4710-4716. PubMed ID: 34131002
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
[TBL] [Abstract][Full Text] [Related]
20. Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial.
Morgan RD; Clamp AR; White DJ; Price M; Burghel GJ; Ryder WDJ; Mahmood RD; Murphy AD; Hasan J; Mitchell CL; Salih Z; Wheeler C; Buckley E; Truelove J; King G; Ainaoui Y; Bhaskar SS; Shaw J; Evans DGR; Kilerci B; Pearce SP; Brady G; Dive C; O'Connor JPB; Wallace AJ; Rothwell DG; Edmondson RJ; Jayson GC
Clin Cancer Res; 2023 Jul; 29(14):2602-2611. PubMed ID: 36799931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
